Trial shows effectiveness of new classes of dual active ingredient insecticidal nets against malaria

IVCC welcomes the publication in The Lancet of the 24-month results of an epidemiological trial in Tanzania, conducted by the London School of Hygiene and Tropical Medicine (LSHTM) in partnership with the National Institute for Medical Research, Kilimanjaro Christian Medical University College, and the University of Ottawa, to assess the public health value of two dual active ingredient nets compared to standard LLINs containing pyrethroids only.

BASF’s, dual active ingredient net, Interceptor® G2 demonstrated a significant reduction in malaria prevalence compared to a pyrethroid only net, with an overall 44% reduction in malaria incidence in children 6 months to 10 years.  In the RoyalGuard® net study arm, while no effect was seen on incidence, there was an indication that the RoyalGuard® net reduced prevalence, although not statistically significant in the Tanzania study.

Our collaboration with BASF on Interceptor® G2 goes back many years so we are delighted to see that our investment in early product development support/field testing, and the continued support of our funding partners, has helped deliver such impactful data.  These results are a significant milestone in establishing the necessary evidence base needed to support an appropriate policy recommendation, and to make dual active ingredient nets a sustainable choice for countries looking for the best value for money in controlling malaria.”

Nick Hamon, CEO of IVCC

Dr Keziah Malm, Programme Manager, National Malaria Control Programme, Ghana Health Service said: “Having access to innovative tools to support insecticide resistance management is critical for countries like Ghana in the fight against malaria. Ghana’s decision to deploy dual active ingredient nets as a pilot was based on our belief that these nets will help us address some of the challenges we were facing with the standard nets. I am very happy to know the study published in the Lancet has shown this: that there can be a significant impact on reducing malaria prevalence with these dual active ingredients nets compared to the standard insecticide-treated nets. I genuinely hope that all stakeholders will put in the needed efforts to get these effective tools deployed to those who need them.”

Dr Philippe Duneton, Executive Director of Unitaid said: “We need better tools to combat mosquito resistance, a growing challenge in the fight against malaria in Africa. The strong performance of the new Interceptor® G2 bed nets in Tanzania is a tremendous step forward, and we are hopeful that these findings, together with research Unitaid is co-funding through the New Nets Project, will bring a powerful new tool to the malaria fight.”

Peter Sands, Executive Director of the Global Fund added: “The strong performance of these innovative insecticide-treated nets is a timely and promising breakthrough which speaks to the power of what public and private partners can achieve when they join forces. As disruptions to malaria services caused by COVID-19 have led to an alarming increase in malaria deaths and cases, these new nets, with other core malaria prevention tools like seasonal malaria chemoprevention, have the potential to help us protect people more effectively, reverse the negative trend and get back on track towards ending malaria by 2030.”

Helen Jamet, Deputy Director, Vector Control, Malaria at the Bill & Melinda Gates Foundation said: “The study results offer new evidence that we can save more children from malaria and help drive down malaria cases by giving countries additional and more effective tools, like the dual-insecticide Interceptor® G2 net, and targeting them where they’re needed most. This also is critical because introducing new tools can help extend the effectiveness of insecticide-treated nets as a category, which prevented 68% of malaria cases in sub-Saharan Africa between 2000-2015.

The results also serve as the latest example of how long-term and innovative public-private partnerships in R&D and financing can deliver high-impact, cost-effective—and in this case, cost-saving—options that are responsive to the needs of endemic countries at a district-by-district level. By using real-time data and improved surveillance to better target the use of new and existing tools and continuing investment in research and development, countries can stay ahead of growing resistance and rapidly drive down malaria cases and deaths to accelerate progress toward eradication.”

UK-based social finance company MedAccess is supporting access to Interceptor® G2 nets in 14 African countries. The company’s volume guarantee has enabled BASF to reduce the price procurers pay for the nets.

Michael Anderson, CEO of MedAccess, said: “These remarkable results from Tanzania are tremendously exciting for everyone who wants to reduce malaria’s burden in Africa. Interceptor® G2’s lifesaving impact, combined with impressive cost-effectiveness data, is a testament to years of partnership to develop, test and implement this effective new tool. We eagerly await the results from the Benin study, which we hope will lead to a WHO recommendation for wider Interceptor® G2 use in Africa.”

24-month data from a second trial in Benin, delivered through the IVCC led New Net Project (NNP), funded by Unitaid and the Global Fund, started one year after the trial in Tanzania, and is expected to be available for WHO review in mid-2022. Both studies will report additional data once the 36-month period is reached and, combined with New Net Pilot evidence pilots across 5 countries, will contribute to the understanding of both Interceptor® G2 and RoyalGuard’s® product performance over time, across various endemicities and resistance profile.

Journal reference:

Mosha, J.F., et al. (2022) Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial. The Lancet.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
World's first malaria vaccine may be available soon across Sub-Saharan Africa